Where Ionis Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 Wall Street analysts have published their opinions on Ionis Pharmaceuticals (NASDAQ:IONS), with an average price target of $52.62, representing an implied upside from the current price of $48.54. The ratings include 3 bullish, 1 somewhat bullish, 3 indifferent, and 1 bearish. The average price target has increased by 45.16% over the past month. Analysts typically review stocks quarterly or after major company updates, basing their predictions on financial analysis and company performance.
November 17, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals has received mixed ratings from analysts, with an average price target of $52.62, which is higher than its current price of $48.54. The price target suggests a potential upside for the stock.
The average price target provided by analysts is a key indicator of the stock's potential performance. With a majority of analysts being bullish or somewhat bullish and the price target indicating an upside, it is likely that investor sentiment will be positively influenced in the short term, potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100